Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Soluble Urokinase Receptor and Acute Kidney Injury

Open access
Hayek, Salim S., Leaf, David E., Samman Tahhan, Ayman, Raad, Mohamad, Sharma, Shreyak, Waikar, Sushrut S., Sever, Sanja, Camacho, Alex, Wang, Xuexiang, Dande, Ranadheer R., Ibrahim, Nasrien E., Baron, Rebecca M., Altintas, Mehmet M., Wei, Changli, Sheikh-Hamad, David, Pan, Jenny S.-C., Holliday, Michael W., Januzzi, James L., Weisbord, Steven D., Quyyumi, Arshed A., Reiser, Jochen · 2020 · New England Journal of Medicine

Abstract

BACKGROUND: Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. We investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and we used experimental models to identify mechanisms by which suPAR acts and to assess it as a therapeutic target. METHODS: We measured plasma levels of suPAR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically ill patients. We assessed the risk of acute kidney injury at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. We also assessed cellular bioenergetics and generation of reactive oxygen species in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR. RESULTS: The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells. CONCLUSIONS: High suPAR levels were associated with acute kidney injury in various clinical and experimental contexts. (Funded by the National Institutes of Health and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1911481

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 211

Metadata

Authors
Hayek, S. S., Leaf, D. E., Samman Tahhan, A., Raad, M., Sharma, S., Waikar, S. S., Sever, S., Camacho, A., Wang, X., Dande, R. R., Ibrahim, N. E., Baron, R. M., Altintas, M. M., Wei, C., Sheikh-Hamad, D., Pan, J. S.-C., Holliday, M. W., Januzzi, J. L., Weisbord, S. D., Quyyumi, A. A., & Reiser, J.
Venue
New England Journal of Medicine
Published
2020-01-30
Volume
382
Issue
5
Pages
416-426
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3004063856
Cited by
211
References
2
FWCI
19.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Soluble Urokinase Receptor and Acute Kidney Injury. https://app.cochat.ai/papers/10.1056/nejmoa1911481
The paper
Hayek, S. S., Leaf, D. E., Samman Tahhan, A., Raad, M., Sharma, S., Waikar, S. S., Sever, S., Camacho, A., Wang, X., Dande, R. R., Ibrahim, N. E., Baron, R. M., Altintas, M. M., Wei, C., Sheikh-Hamad, D., Pan, J. S.-C., Holliday, M. W., Januzzi, J. L., Weisbord, S. D., . . . Reiser, J. (2020). Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1911481

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.